{
  "id": 16295912,
  "title": "Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026",
  "url": "https://urgent.news/2026/10/24/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha",
  "topic": "world",
  "section": "World",
  "published": "2026-10-24T06:31:53.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-antibody-drug-conjugate-zw191-at-esmo-congress-2026"
  },
  "original_language": "en",
  "account": null,
  "summary": "ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels Confirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer Median duration of response not yet reached at either dose level at median 7 months…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}